Steele Tace, Pawaskar Manjiri, Balkrishnan Rajesh, Fleischer Alan, Feldman Steven R
Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 2715-1071, USA.
Dermatol Ther. 2007 Mar-Apr;20(2):110-9. doi: 10.1111/j.1529-8019.2007.00119.x.
Cost is a measure of resources consumed. By assessing costs, pharmacoeconomic studies complement studies of efficacy and safety, helping to determine the relationships of treatment and outcome. Costs are divided into three categories, including direct cost (resources attributable to the intervention), indirect cost (resulting from reduced productivity), and intangible cost (incurred from pain and emotional suffering). Insurance companies, patients, doctors, and the society all have different perspectives with respect to costs. The present authors review different types of cost analyses and their use in studies of psoriasis, atopic dermatitis, and basal cell carcinoma treatment. Cost studies influence clinicians, policy makers, and third-party payers' decisions regarding the implementation of particular therapies or programs. Collection of cost data needs to be incorporated into clinical trials to facilitate these decisions.
成本是对所消耗资源的一种衡量。通过评估成本，药物经济学研究对疗效和安全性研究起到补充作用，有助于确定治疗与结果之间的关系。成本分为三类，包括直接成本（归因于干预措施的资源）、间接成本（因生产力下降产生）和无形 成本（由疼痛和情感痛苦引起）。保险公司、患者、医生和社会对于成本都有不同的观点。本文作者综述了不同类型的成本分析及其在银屑病、特应性皮炎和基底细胞癌治疗研究中的应用。成本研究影响临床医生、政策制定者和第三方支付者关于实施特定治疗或项目的决策。成本数据的收集需要纳入临床试验以促进这些决策。
